Madrigal Pursues $500M Public Offering with NASH Market Up for Grabs

Madrigal Pharmaceuticals on Thursday said it’s looking to make around $500 million in gross proceeds from a public offering, with the net proceeds supporting its clinical and commercial activities leading up to the potential launch of its nonalcoholic steatohepatitis therapy resmetirom.